Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

31.83B

Market cap31.83B

Price-Earnings ratio

37.32

Price-Earnings ratio37.32

Dividend yield

—

Dividend yield—

Average volume

687.55K

Average volume687.55K

High today

$216.70

High today$216.70

Low today

$208.93

Low today$208.93

Open price

$210.09

Open price$210.09

Volume

916.93K

Volume916.93K

52 Week high

$225.80

52 Week high$225.80

52 Week low

$135.39

52 Week low$135.39

Stock Snapshot

The current Biogen(BIIB) stock price is $215.43, with a market capitalization of 31.83B. The stock trades at a price-to-earnings (P/E) ratio of 37.32.

During the trading session on 2026-09-10, Biogen(BIIB) shares reached a daily high of $216.70 and a low of $208.93. At a current price of $215.43, the stock is +3.1% higher than the low and still -0.6% under the high.

Trading volume for Biogen(BIIB) stock has reached 916.93K, versus its average volume of 687.55K.

The stock's 52-week range extends from a low of $135.39 to a high of $225.80.

BIIB News

Investing.com 8h

Stifel reiterates Biogen stock rating on immunology pipeline - Investing.com

...

TipRanks 10h

Biogen price target raised to $175 from $165 at HSBC

HSBC raised the firm’s price target on Biogen (BIIB) to $175 from $165 and keeps a Reduce rating on the shares. The firm adjusted targets in the healthcare grou...

Simply Wall St 7d

Biogen, Why Is Its Latest Update Drawing Fresh Attention?

Biogen (BIIB) is back in focus after the U.S. launch of LEQEMBI IQLIK, a once weekly at home subcutaneous version of its Alzheimer’s treatment that replaces cli...

Analyst ratings

67%

of 36 ratings

Buy

66.7%

Hold

30.6%

Sell

2.8%

More BIIB News

TipRanks 7d

Stoke Therapeutics, Biogen present long-term data on Zorevunersen

“Stoke Therapeutics (STOK) and Biogen Inc. (BIIB) announced presentations of data at the 16th European Epilepsy Congress taking place September 5-9 in Athens, G...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.